Management of blood pressure in stroke.

AIS, acute ischemic stroke BP, blood pressure BPV, blood pressure variability CBF, cerebral blood flow Hypertension IPH, intraparenchymal hemorrhage of the brain Prevention Stroke tPA, tissue plasminogen activator (alteplase)

Journal

International Journal of Cardiology. Hypertension
ISSN: 2590-0862
Titre abrégé: Int J Cardiol Hypertens
Pays: Netherlands
ID NLM: 101773659

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 15 09 2019
accepted: 09 10 2019
entrez: 15 1 2021
pubmed: 13 10 2019
medline: 13 10 2019
Statut: epublish

Résumé

In this review and opinion piece, we discuss recent United States (US)-based guidance statements on the management of BP in stroke according to stroke type and stage of stroke. We reviewed the most recent guidance statements on BP control from United States (US)-based organizations such as the American Heart Association/American Stroke Association (AHA/ASA) and American College of Cardiology (ACC), and articles available to the authors in their personal files. The key BP target before starting alteplase (t-PA) is < 185/110 mm Hg, and the maintenance BP after tPA administration is < 180/105 mm Hg. For IPH patients with systolic BP between 150 and 220 mm Hg and no contraindication to acute BP reduction therapy, acute lowering to 140 mm Hg systolic BP is safe. For persons with small vessel or lacunar cerebral ischemia, a reasonable BP lowering target is < 130 mm Hg systolic. For primary stroke prevention, the target BP for those with hypertension is < 140/90 mm Hg and self-measured BP is recommended to assist in BP control. Recent study and guidance suggest a BP target of <130/80 mm Hg for both primary and recurrent stroke prevention. BP control is reasonable for the prevention of cognitive decline or dementia. BP targets for the proper management of stroke vary by chronological stage of stroke and by stroke subtype. Furthermore, consideration should be given to control of BP variability, especially in the acute phases of stroke, as it may play a role in conferring longer term outcomes.

Identifiants

pubmed: 33447751
doi: 10.1016/j.ijchy.2019.100021
pii: S2590-0862(19)30021-7
pmc: PMC7803067
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

100021

Informations de copyright

© 2019 Published by Elsevier B.V.

Références

Stroke. 2011 Sep;42(9):2672-713
pubmed: 21778438
JAMA Neurol. 2019 May 13;:
pubmed: 31081862
Stroke. 2014 Dec;45(12):3754-832
pubmed: 25355838
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
Trends Cardiovasc Med. 2019 Jan;29(1):12-18
pubmed: 29891330
J Am Coll Cardiol. 2018 May 15;71(19):2176-2198
pubmed: 29146534
Neurology. 2006 Aug 22;67(4):567-71
pubmed: 16924005
J Am Soc Hypertens. 2012 Sep-Oct;6(5):309-15
pubmed: 22995799
Brain Sci. 2019 Jan 23;9(2):
pubmed: 30678095
N Engl J Med. 2016 Sep 15;375(11):1033-43
pubmed: 27276234
Lancet Neurol. 2019 Sep;18(9):857-864
pubmed: 31397290
Neurology. 2018 Oct 16;91(16):729-730
pubmed: 30232249
JAMA. 2019 Aug 13;322(6):524-534
pubmed: 31408137
Lancet. 2019 Mar 2;393(10174):877-888
pubmed: 30739745
Stroke. 2009 Jun;40(6):2251-6
pubmed: 19390077
N Engl J Med. 2013 Jun 20;368(25):2355-65
pubmed: 23713578
Stroke. 2017 Oct;48(10):e284-e303
pubmed: 28883125
Stroke. 2018 Feb;49(2):275-276
pubmed: 29301975
Stroke. 2018 Aug;49(8):1836-1842
pubmed: 30012819
Lancet Neurol. 2002 Jul;1(3):149-56
pubmed: 12849483
Neurol Clin. 2016 Aug;34(3):467-82
pubmed: 27445238
JAMA Neurol. 2019 Jul 29;:
pubmed: 31355878
J Am Soc Hypertens. 2015 May;9(5):331-3
pubmed: 25979408
Stroke. 2015 Jul;46(7):2032-60
pubmed: 26022637
JAMA Intern Med. 2019 Aug 19;:
pubmed: 31424475
Lancet. 2019 Mar 9;393(10175):1009-1020
pubmed: 30738649
Hypertension. 2018 Jun;71(6):e13-e115
pubmed: 29133356
Neurology. 2012 Nov 13;79(20):2018-24
pubmed: 23054228
Curr Cardiol Rep. 2013 Jun;15(6):366
pubmed: 23605468
JAMA. 2014 Feb 5;311(5):479-89
pubmed: 24240777
Ann Neurol. 2012 Feb;71(2):199-205
pubmed: 22367992
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
N Engl J Med. 2000 Jan 20;342(3):145-53
pubmed: 10639539
Stroke. 2019 Aug;50(8):2023-2029
pubmed: 31216966
J Neurochem. 2018 Mar;144(5):609-616
pubmed: 28677324
Hypertension. 2017 Jan;69(1):171-179
pubmed: 27802419
Stroke. 2019 Aug;50(8):2016-2022
pubmed: 31272326
J Hypertens. 2015 Oct;33(10):2099-106
pubmed: 26237556
Stroke. 2018 Jan;49(1):46-53
pubmed: 29203686
JAMA Neurol. 2014 Oct;71(10):1211-3
pubmed: 25090029
Lancet. 2015 Feb 14;385(9968):617-628
pubmed: 25465108
Lancet. 2001 Sep 29;358(9287):1033-41
pubmed: 11589932
Lancet. 2010 Mar 13;375(9718):938-48
pubmed: 20226991
JAMA. 2019 Feb 12;321(6):553-561
pubmed: 30688979

Auteurs

Philip B Gorelick (PB)

Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Department of Translational Neuroscience, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.

Shakaib Qureshi (S)

Hauenstein Neurosciences, 220 Cherry Street SE, Grand Rapids, MI 49503, USA.

Muhammad U Farooq (MU)

Hauenstein Neurosciences, 220 Cherry Street SE, Grand Rapids, MI 49503, USA.

Classifications MeSH